ACADIA Pharmaceuticals


Top Analyst Stands Firm for Acadia Pharmaceutical (ACAD) Stock While its Anti-Depression Medication Goes Through Trial

After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …

Here’s Why ACADIA Pharmaceuticals Stock Is Plummeting 25% Today

ACADIA Pharmaceuticals (NASDAQ:ACAD) just got hit with a bad bullet: a CNN research report questioning lead asset Nuplazid’s risk/reward as a treatment of …

Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia

Billionaire Israel “Izzy” Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with …

ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s Opportunity

ACADIA Pharmaceuticals (NASDAQ:ACAD) just yielded a third quarter outclass that has one of the Street’s top analysts impressed in the upshot. What commercial …

ACADIA Pharmaceuticals Inc. (ACAD) Gets a Price Target Jump; Here’s Why

One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.

ACADIA Pharmaceuticals Inc.’s (ACAD) Phase II Study in Alzheimer’s Disease Psychosis Faces Criticism; Top Analyst Weighs In

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) tumbled nearly 9% in Monday’s trading session, after the drug maker announced the presentation of data from the …

ACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with Severe Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer’s disease psychosis at the …